⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2230505 | 0.99 | — | — | |
| Bromide SCHEMBL2036664 | 0.99 | — | — | |
| Pibrozelesin SCHEMBL14499178 | 0.79 | P4HB (0.44) | — | |
| SCHEMBL13401608 | 0.76 | TSHR (0.34) | — | |
| SCHEMBL14012308 | 0.76 | TSHR (0.34) | — | |
| SCHEMBL13410096 | 0.76 | HRH4 (0.34) | — | |
| SCHEMBL13401541 | 0.74 | HRH4 (0.34) | — | |
| SCHEMBL14012235 | 0.71 | HRH4 (0.45) | — | |
| SCHEMBL13401447 | 0.71 | SYK (0.39) | — | |
| SCHEMBL7469393 | 0.70 | P4HB (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20260102394-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2026-04-16 | — | — | US | disclosed |
| EP-4676602-A1 | COMPOUNDS TARGETING MUTATIONS IN P53 AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12458640-B2 | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-11-04 | — | — | US | disclosed |
| CN-114206885-B | Pyrazolo [3,4-B ] pyrazines SHP2 phosphatase inhibitors | 大冢制药株式会社 | 2025-05-02 | — | — | CN | disclosed |
| WO-2024187153-A1 | COMPOUNDS TARGETING MUTATIONS IN P53 AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20230049719-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-02-16 | — | — | US | disclosed |
| US-20220304993-A1 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2022-09-29 | — | — | US | disclosed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | disclosed |
| EP-1653967-A2 | COMBINATION OF A COX-2 INHIBITOR AND AN ALKYLATING-TYPE ANTINEOPLASTIC AGENT FOR TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050214366-A1 | Anti-first-pass effect compounds | BIOAVAILABILITY SYSTEMS, LLC (US) | 2005-09-29 | — | — | US | disclosed |
| WO-2004093856-A2 | COMBINATION OF A COX-2 INHIBITOR AND AN ALKYLATING-TYPE ANTINEOPLASTIC AGENT FOR TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040072889-A1 | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia | PHARMACIA CORPORATION | 2004-04-15 | — | — | US | disclosed |
| US-20040058982-A1 | Pharmaceutical compositions | BIOAVAILABILITY SYSTEM, LLC (US) | 2004-03-25 | — | — | US | disclosed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | disclosed |